Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 2 4Phase EARLY_PHASE1 1Phase 2/3 1Phase 1 1

Status

Recruiting 8Active not recruiting 5Completed 2Unknown 1Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Prostatic Neoplasms 5Urogenital Neoplasms 1Neoplasms 1Neoplasm Metastasis 1

Interventions

Carboplatin 107Cisplatin 97Paclitaxel 79pembrolizumab 69Gemcitabine 59Pemetrexed 49Cyclophosphamide 47Docetaxel 46Dexamethasone 45durvalumab 44Capecitabine 44Radiotherapy 41Doxorubicin 38Nivolumab 37Lenalidomide 37Specimen Handling 36Oxaliplatin 35Rituximab 34Fluorouracil 33Bevacizumab 33Magnetic Resonance Spectroscopy 32Etoposide 30atezolizumab 29Vincristine 28Radiation 27Leucovorin 27Letrozole 24Bortezomib 24Fulvestrant 23Prednisone 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Active not recruiting × abiraterone × Clear all
NCT06691984 2026-05-15

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

Amgen

Phase 3 Active not recruiting
707 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT04647526 2026-01-13

SPLASH

Eli Lilly and Company

Phase 3 Active not recruiting
455 enrolled 18 charts
Genitourinary

Prostatic Neoplasms

NCT04446117 2025-12-18

CONTACT-02

Exelixis

Phase 3 Active not recruiting
575 enrolled 13 charts
Genitourinary

Prostatic Neoplasms

NCT05204927 2025-07-31

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

Curium US LLC

Phase 3 Active not recruiting
439 enrolled
Genitourinary

Prostatic Neoplasms

NCT05288166 2025-06-27

CYCLONE 3

Eli Lilly and Company

Phase 3 Active not recruiting
925 enrolled 12 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡